[Skip to Navigation]
Observation
April 8, 2020

Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies

Author Affiliations
  • 1Division of Dermatology, Washington University in St Louis, St Louis, Missouri
  • 2Boonshoft School of Medicine, Wright State University, Dayton, Ohio
  • 3Siteman Cancer Center, Washington University in St Louis, St Louis, Missouri
  • 4Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri
JAMA Dermatol. 2020;156(5):601-603. doi:10.1001/jamadermatol.2020.0208

Antibody drug conjugate (ADC) therapies are an emerging treatment for hematologic and solid organ malignant tumors. These ADCs are targeted monoclonal antibodies conjugated to a cytotoxic payload, designed to maximize antitumor effect while minimizing toxic effects to normal host tissue.1 We describe a case series of 6 patients who presented with a similar telangiectatic rash after treatment with ADCs containing the cytotoxic payload tesirine.

Add or change institution
×